Evidence map›Paper›PMID 31127456›Full record

Trial reportInternational journal of hematology2019

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

Yosuke Matsumoto, Tsutomu Kobayashi, Yuji Shimura, Eri Kawata, Hisao Nagoshi, Muneo Ohshiro, Mio Sugitani, Kazuho Shimura, Toshiki Iwai, Shin-Ichi Fuchida and 16 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 1 country.

Yosuke MatsumotoDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Honmachi, Higashiyama-ku, Kyoto, 605-0981, Japan. yosuke-m@koto.kpu-m.ac.jp.ORCID http://orcid.org/0000-0001-7416-3222
Tsutomu KobayashiDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yuji ShimuraDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Eri KawataDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hisao NagoshiDepartment of Hematology and Oncology, Hiroshima University, Hiroshima, Japan.
Muneo OhshiroDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Honmachi, Higashiyama-ku, Kyoto, 605-0981, Japan.
Mio SugitaniDepartment of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
Kazuho ShimuraDepartments of Hematology and Laboratory Medicine, Aiseikai Yamashina Hospital, Kyoto, Japan.
Toshiki IwaiDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Honmachi, Higashiyama-ku, Kyoto, 605-0981, Japan.
Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Mihoko YoshidaDepartments of Hematology and Laboratory Medicine, Aiseikai Yamashina Hospital, Kyoto, Japan.
Miki KiyotaDepartment of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan.
Shinsuke MizutaniDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoshiaki ChinenDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tomoko Takimoto-ShimomuraDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Mitsushige NakaoDepartment of Hematology, Otsu City Hospital, Otsu, Japan.
Hiroto KanekoDepartments of Hematology and Laboratory Medicine, Aiseikai Yamashina Hospital, Kyoto, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Honmachi, Higashiyama-ku, Kyoto, 605-0981, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Hikari NishigakiDepartment of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan.
Yutaka KobayashiDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Shigeo HoriikeDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Masafumi TaniwakiDepartments of Hematology and Laboratory Medicine, Aiseikai Yamashina Hospital, Kyoto, Japan.
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kyoto Clinical Hematology Study Group (KOTOSG)
Kyoto Prefectural University of Medicine · JPKyoto first Red Cross hospital · JPJapanese Red Cross Society Kyoto Daini Hospital · JPKyoto Medical Center · JPMatsushita Memorial Hospital · JPFukuyama City Hospital · JPHiroshima University · JPOtsu Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This multicenter phase II study (UMIN000008145) aims to investigate the efficacy and safety of six cycles of combination therapy (RBD) comprising rituximab, bendamustine, and dexamethasone (DEX) for relapsed or refractory (RR) indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL). Although the initial study protocol comprised 20 mg/body DEX on days 1 and 2, and 10 mg/body on days 3-5 [high-dose (HD-) DEX group], the dose of DEX was later decreased to 8 mg/body on days 1 and 2 [low-dose (LD-) DEX group] due to frequent cytomegalovirus (CMV) antigenemia and recurrent retinitis. We enrolled 33 patients, and LD-DEX and HD-DEX were administered in 15 and 18 patients, respectively. The overall response and the 3-year progression-free survival rates were 88% and 75.5%, respectively. The leading adverse event was myelosuppression. Incidence of grade 3-4 leukocytopenia, neutropenia, and lymphocytopenia was 55%, 67%, and 91%, respectively. The most frequent nonhematological adverse events were CMV antigenemia and rash (33% and 30%, respectively). Incidence of CMV antigenemia over 10/100,000 white blood cells was significantly lower with LD-DEX than that with HD-DEX (P = 0.0127). In conclusion, RBD showed significant effectiveness for RR indolent B-NHL and MCL.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideCytomegalovirus InfectionsDexamethasoneDrug Administration ScheduleFemaleHumansLeukopeniaLymphoma, B-CellLymphoma, Mantle-CellMaleMiddle AgedNeutropeniaRituximabBendamustine HydrochlorideDexamethasoneRituximabBendamustineDexamethasoneIndolent B-cell non-Hodgkin lymphomaMantle cell lymphomaRituximab

Identifiers

PMID31127456
OpenAlexW2945410420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.